Why the study?
Does infliximab improve coronary artery aneurysm in a 1-month-old girl with refractory Kawasaki disease?
Does infliximab improve coronary artery aneurysm in a 1-month-old girl with refractory Kawasaki disease?
Infliximab may be an effective treatment for refractory Kawasaki disease complicated by coronary artery aneurysm in infants.
Infliximab may aid aneurysm regression in refractory infantile Kawasaki disease; hypothesis-generating and requires prospective trials.
Tumor necrosis factor-alpha (TNF-alpha) is considered to be 1 of the factors that induce vasculitis, including coronary artery aneurysm (CA), in Kawasaki disease (KD), because the blood concentration of TNF-alpha is higher in patients with CA compared with those without. Therefore, an anti-TNF-alphaagent (infliximab) was administered to a 1-month-old girl with refractory KD complicated by CA and subsequently, the CA improved and KD was controlled without complications 20 months after the onset.
No takes yet. Share an insight, caveat, or question.
Oishi et al. (2008) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: